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Sergio Giralt,1 Karen Ballen,2 Douglas Rizzo,3 Andreas Bacigalupo,4 Mary Horowitz,3
Marcelo Pasquini,3 Brenda Sandmaier5During the 2006 BMTTandemMeetings, aworkshopwas convened by theCenter for International Blood and
Marrow Transplant Research (CIBMTR) to discuss conditioning regimen intensity and define boundaries of
reduced-intensity conditioning (RIC) before hematopoietic cell transplantation (HCT). The goal of thework-
shop was to determine the acceptance of available RIC definitions in the transplant community. Participants
were surveyed regarding their opinions on specific statements on conditioning regimen intensity. Questions
covered the ‘‘Champlin criteria,’’ as well as operational definitions used in registry studies, exemplified in clin-
ical vignettes. A total of 56 participants, including transplantation physicians, transplant center directors, and
transplantation nurses, with a median of 12 years of experience in HCT, answered the survey. Of these, 67%
agreed that a RIC regimen should cause reversible myelosuppression when administered without stem cell
support, result in lownonhematologic toxicity, and, after transplantation, result inmixed donor–recipient chi-
merism at the timeof first assessment inmost patients. Likewise, themajority (71%) agreedor strongly agreed
that regimens including\ 500 cGy of total body irradiation as a single fraction or 800 cGy in fractionated
doses, busulfan dose\9 mg/kg, melphalan dose\140 mg/m2, or thiotepa dose\10 mg/kg should be con-
sidered RIC regimens. However, only 32% agreed or strongly agreed that the combination of carmustine,
etoposide, cytarabine, and melphalan (BEAM) should be considered a RIC regimen. These results demon-
strate that although HCT professionals have not reached a consensus on what constitutes a RIC regimen,
most accept currently used criteria and operational definitions. These results support the continued use of
current criteria for RIC regimens until a consensus statement can be developed.
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Patients undergoing allogeneic hematopoietic stem
cell transplantation (HCT) are prepared with chemo-
therapy and/or radiotherapy to reduce the tumor
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6/j.bbmt.2008.12.497etic cells [1]. Increasing the dose intensity of the
conditioning regimen to improve outcomes by reduc-
ing the risk of relapse has produced no major changes
in survival, because of increases in nonrelapsemortality
(NRM) that offset any benefits obtained from better
disease control [2].
The past decade has seen a major paradigm shift in
the field of HCT. In an effort to explore graft-versus-
disease effects without major regimen-related toxicity,
many investigators have lowered the dose of radiation
or alkylating agents used in the conditioning regimen
[2-8]. These regimens are known as nonmyeloablative
(NMA) or reduced-intensity conditioning (RIC) regi-
mens. This nomenclature was chosen because many of
these regimens are administered without stem cell sup-
port, and the doses of agents delivered are substantially
lower than those used in a traditional conditioning
regimen.
Defining what constitutes a RIC regimen is an im-
portant issue that the transplantation community367
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prospective analyses of different regimens. At the First
International Workshop of Nonmyeloablative Stem
Cell Transplantation, Dr Richard Champlin proposed
a set of criteria that an RIC regimen should fulfill [9].
These so-called ‘‘Champlin criteria’’ define as reduced
intensity any regimen that does not require stem cell
support for hematopoietic recovery and that results
in low nonhematologic toxicity and mixed donor–
recipient chimerism in a substantial proportion of pa-
tients in the early posttransplantation period (around
day 130) [9,10].
As part of the initial retrospective analysis of the
outcomes of RIC regimens in recipients of unrelated
donor hematopoietic stem cells, the National Marrow
Donor Program (NMDP) and the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR) had a Expert Panel develop an operational
definition of what regimens should be considered RIC
[11]. Even though these definitions were based as
much as possible on available data, they still reflect
the Panel members’ biases and opinions, and they are
not universally accepted, although similar definitions
have been adopted by the European Bone Marrow
Transplant Registry (EBMT) [12-14]. To assess the
acceptability of these criteria, a workshop was con-
vened during the 2006 BMT Tandem Meeting. Here
we summarize the findings of this workshop.Table 1. Characteristics of Survey Respondents
Number of respondents 56
Age, years, median (range) 48 (30 to 60)
Male sex, n 43
Occupation, n
MD > 50% clinic 40
MD < 50% clinic 14
Nurse 2
Years of SCTexperience, median (range) 12 (0 to 52)*
Annual number of SCTs, median (range) 140 (0 to 900)*
*One respondent was a retired transplantation physician and a current
transplant recipient who currently works for a pharmaceutical company.
Another respondent had just finished her residency and was planning to
travel to the Amazon region for 3 weeks.METHODS
During the 2006 BMT Tandem meeting, the Or-
ganizing Committee assigned Drs Sergio Giralt and
Brenda Sandmaier to chair a workshop addressing the
issue of defining regimen intensity. The chairs agreed
that they would use the workshop to demonstrate the
acceptability of current available criteria for RIC regi-
mens among the transplantation community, and pro-
pose modifications as deemed appropriate. To achieve
theworkshop’s primary goal, a surveywas administered
to persons representing various groups in the trans-
plantation community, including workshop attendees,
members of theCIBMTR’sRegimen-RelatedToxicity
Working Committee, members of the Blood andMar-
row Transplant Clinical Trials Network (BMTCTN)
Steering and Toxicity Committees, and randomly
selected transplantation program directors. The survey
comprised a series of questions, some illustrated
through clinical vignettes, regarding currently used
criteria for RIC regimens, as well as operational defini-
tions used by the CIBMTR to determine whether
a specific regimen or combination of agents should be
considered an RIC regimen.
Participants were instructed to state whether they
strongly agreed, agreed, disagreed, or strongly dis-
agreed with specific statements. The first assessment
included questions related to the acceptability of theChamplin criteria in defining the general characteris-
tics of an RIC regimen (9). According to these criteria,
an RIC regimen results in reversible myelosuppression
(usually within 28 days) when given without stem cell
support, results in mixed chimerism in a proportion
of patients at the time of first assessment (usually 28
to 35 days after stem cell transplantation), and has
a low rate of nonhematologic toxicity. The second
assessment evaluated the transplantation community’s
acceptance of the operational definitions used by the
NMDP and the CIBMTR for retrospective analysis
(11). This operational definition identifies as an RIC
regimen any regimen that includes (a) total body irra-
diation (TBI) of # 500 cGy as a single fraction or #
800 cGy if fractionated, (b)\9 mg/kg of oral busulfan
(or intravenous equivalent), (c)\ 140 mg/m2 of mel-
phalan, (d) \ 10 mg/kg of thiotepa, (e) the BEAM
regimen (carmustine, etoposide, cytarabine, and mel-
phalan) (15). The results were collected and summa-
rized using descriptive statistical methods.RESULTS
A total of 56 HCT professionals, representing 44
institutions from 9 different countries, answered the
survey. Their demographic information, as well as
other characteristics, are summarized in Table 1.Champlin Criteria
Of the 56 respondents, 67% either strongly agreed
or agreed to the first criterion regarding reversible
myelosuppression, and 71% either agreed or strongly
agreed with the next 2 criteria for what constitutes an
RIC regimen.These results are summarized inTable 2.NMDP/CIBMTR Operational Definitions
More than 60% of the respondents agreed or
strongly agreed with the first 4 operational definitions
of what constituted an RIC regimen, however, only
32% agreed or strongly agreed that the BEAM combi-
nation qualified as an RIC regimen. These data are
summarized in Table 3.
Table 2. Acceptance of the Champlin Criteria as the Char-
acteristics Defining an RIC Regimen
Criteria
Strongly
Agree, n Agree, n
% that
Strongly Agree
or Agree
Results in reversible
myelosuppression (usually
within 28 days) when given
without stem cell support
26 12 67
Results in mixed chimerism in
a proportion of patients at
the time of first assessment
18 22 71
Associated with a low rate of
nonhematologic toxicity
18 22 71
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Defining conditioning intensity has become an im-
portant goal for the transplantation community as the
use of RIC continues to increase [15]. Criteria as well
as operational definitions for what constitutes a RIC
regimen are essential for performing retrospective
analyses comparing RIC and non-RIC regimens. In
a previous retrospective analysis of the CIBMTR and
NMDP database, an Expert Panel provided both crite-
ria and operational definitions for RIC regimens
[9-11]. Similar work was done by the EBMT,with sim-
ilar, although not identical, results [12-14].
The findings of our survey suggest that the Cham-
plin criteria for defining an RIC regimen seem to be
widely acceptable. Likewise, 4 of the 5 proposed oper-
ational definitions were deemed acceptable by at least
2/3 of the respondents. Only the inclusion of the
BEAM regimen was not generally accepted; only
32% of the respondents agreed that BEAM conforms
with the criteria for an RIC.
Ultimately, the definition of what constitutes
a RIC regimen is also determined by what we define
as a myeloablative regimen (ie, a conditioning regimen
that cannot be administered without stem cell sup-
port). Defining myeloablative conditioning regimens
would allow for everything else to be considered an
RIC conditioning regimen by default. The CIBMTR
and the EBMT are currently working on a consensus
statement regarding this issue, which should help
clarify nomenclature as well as provide guidelines for
classifying novel regimens under investigation. UntilTable 3. Acceptance of the NMDP Operational Criteria for
RIC Regimens
Criteria
Strongly
Agree, n Agree, n % in Top 2
TBI # 500 cGy as a single
fraction or # 800 cGy
if fractionated
16 19 62
Total busulfan # 9 mg/kg 15 27 75
Total melphalan #
140 mg/m2
13 29 75
Thiotepa < 10 mg/kg 9 28 62
BEAM 1 17 32such a statement is adopted, the findings from this
workshop support continued use of the proposed
guidelines and operational definitions.ACKNOWLEDGMENTS
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